Table 3.
Cox regression analysis for percent life expectancy
| Variable | Significance | HR |
95%CI for HR |
|
| Lower | Upper | |||
| Gender | 0.072 | 0.717 | 0.499 | 1.030 |
| HBsAg | 0.043 | 1.709 | 1.018 | 2.869 |
| anti-HCV | 0.043 | 1.597 | 1.015 | 2.511 |
| AFP | 0.000 | 1.348 | 1.145 | 1.587 |
| L3 | 0.421 | 1.004 | 0.995 | 1.012 |
| DCP | 0.015 | 1.243 | 1.043 | 1.482 |
| Child-Pugh class | ||||
| A | 0.001 | |||
| B | 0.001 | 2.144 | 1.393 | 3.300 |
| C | 0.084 | 2.375 | 0.891 | 6.332 |
| Tumor stage1 | ||||
| I | 0.000 | |||
| II | 0.554 | 1.216 | 0.637 | 2.320 |
| III | 0.180 | 1.554 | 0.816 | 2.960 |
| IV | 0.000 | 3.879 | 1.871 | 8.045 |
| Therapy category | ||||
| Loco-regional | 0.000 | |||
| IVR | 0.000 | 2.755 | 1.816 | 4.179 |
| Chemotherapy | 0.000 | 3.365 | 1.884 | 6.010 |
| Others | 0.246 | 3.359 | 0.435 | 25.971 |
| Age group | ||||
| 49 years/younger | 0.240 | |||
| 50s | 0.242 | 0.598 | 0.253 | 1.415 |
| 60s | 0.107 | 0.496 | 0.211 | 1.164 |
| 70s | 0.047 | 0.436 | 0.192 | 0.990 |
| 80 years/older | 0.041 | 0.348 | 0.126 | 0.958 |
General rules for the clinical and pathological study of primary liver cancer from Liver Cancer Study Group of Japan; HR: Hazard ratio; AFP:α-fetoprotein; L3: Percentage of fucosylated fraction in AFP; DCP: Des-γ-carboxy prothrombin; Loco-regional: Therapies including resection, radiofrequency ablation, microwave coagulation and percutaneous ethanol injection; IVR: Interventional radiology including transcatheter arterial chemoembolization, and transarterial oily chemoembolization; Chemotherapy: Therapies including hepatic arterial infusion chemotherapy, systemic chemotherapy and molecular targeting therapy; Others: Other therapies including stereotactic body radiation, proton beam and liver transplantation; HCV: Hepatitis C virus; HBsAg: Hepatitis B surface antigen.